Every 10-Q that Longeveron Inc. (LGVN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LGVN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LGVN filings page.
Longeveron Inc., a clinical-stage biotech focused on regenerative cell therapies, reported a net loss of $10.8 million for the six months ended June 30, 2026, on revenue of $0.7 million, primarily from clinical trial activity. Operating expenses remained high at $11.4 million, reflecting research and development and general and administrative spending.
Cash and cash equivalents increased to $10.1 million from $4.7 million at year-end 2025, driven mainly by $13.5 million of net equity proceeds from a March 2026 private placement, $1.4 million from warrant exercises, and $0.9 million from the sale of an interest in 50% of potential PRV proceeds. Stockholders’ equity rose to $10.4 million.
The company states that existing cash is expected to fund operations only into the fourth quarter of 2026 and that additional financing will be required. Management’s cash flow forecast indicates insufficient resources to meet minimum commitments over 12 months, leading to disclosed substantial doubt about the ability to continue as a going concern. Subsequent to quarter-end, Longeveron was named a finalist in the XPRIZE Healthspan competition, entitling it to a $1.0 million milestone award earmarked for a future clinical trial.
Longeveron Inc. reported March 31, 2026 quarter results showing total revenue of $0.4M and a net loss of $4.7M, slightly improved from a $5.0M loss a year earlier. Cash and cash equivalents rose to $15.8M, helped by an initial private placement that raised roughly $15.9M and warrant exercises.
Total assets increased to $21.2M, with stockholders’ equity expanding to $16.0M. However, the company has an accumulated deficit of $137.0M and expects to continue incurring operating losses as it advances laromestrocel, its lead regenerative medicine candidate, through clinical development.
Management expects existing cash, including private placement proceeds, to fund operations into the fourth quarter of 2026, but its forecast shows insufficient cash to cover minimum commitments for 12 months. As a result, Longeveron discloses substantial doubt about its ability to continue as a going concern and indicates it must secure additional financing or revise its operating plan.
Longeveron Inc. reported Q3 2025 results marked by much lower revenue and a wider loss as the company advances its lead cell therapy program. Total revenue was $137k for the quarter, down from $773k a year ago, reflecting a sharp decline in contract manufacturing activity. Net loss was $7.221M versus $4.419M in Q3 2024.
Cash and cash equivalents were $9.244M as of September 30, 2025. Management states this should fund operations late into Q1 2026 based on the current plan, and it has an ATM facility up to $10.7M in aggregate market value. The filing notes substantial doubt about the company’s ability to continue as a going concern without additional financing.
For the nine months ended September 30, 2025, revenue was $834k (vs. $1.789M in 2024) and net loss was $17.260M (vs. $11.892M). Operating expenses rose, with R&D at $9.321M and G&A at $9.113M. The company is prioritizing its HLHS program and anticipates a potential BLA filing in 2027 if the current ELPIS II trial is successful. As of October 31, 2025, shares outstanding were 19,848,876 Class A and 1,484,005 Class B.
Longeveron Inc. (LGVN) reported unaudited results for the quarter ended June 30, 2025 showing continued clinical-stage operations with rising costs and constrained liquidity. Cash and cash equivalents declined to $10.3 million from $19.2 million at year-end, and the company recorded a $10.0 million net loss for the six months ended June 30, 2025, widening from $7.5 million a year earlier. Revenue for the six months was $0.7 million, down from $1.0 million, while research and development and general and administrative expenses increased, driving an operating loss of $10.6 million for the period.
The company disclosed a $119.6 million accumulated deficit and stated it does not have sufficient cash to meet minimum expenditures for one year without additional financing, creating substantial doubt about its ability to continue as a going concern. Management cites completed financing activity and expects current cash to fund operations into the first quarter of 2026 based on its budget. Regulatory progress includes a Type C FDA meeting for the HLHS pathway and a Type B FDA meeting for Alzheimer’s, and the company is ramping BLA-enabling and manufacturing readiness activities, contingent on trial success and additional funding.